--Whistleblower Claims Boeing Supplier Spirit AeroSystems Regularly Shipped Defective Fuselages, CBS News Says-March 2024-www.financetom.com

--Whistleblower Claims Boeing Supplier Spirit AeroSystems Regularly Shipped Defective Fuselages, CBS News Says

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Whistleblower Claims Boeing Supplier Spirit AeroSystems Regularly Shipped Defective Fuselages, CBS News Says

May 9, 2024 5:30 AM

08:04 AM EDT, 05/09/2024 (MT Newswires) --

Price: 179.55, Change: -0.80, Percent Change: -0.44

Previous page： Mortgage Companies Poised For Mixed Quarterly Results, UBS Says Next page： Central Bancompany files for US IPO

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Mortgage Companies Poised For Mixed Quarterly Results, UBS Says

Oct 10, 2025

04:54 PM EDT, 10/10/2025 (MT Newswires) -- US mortgage companies are poised to report mixed third-quarter results, while a drop in interest rates last month likely drove refinancing activity higher as the September period closed out, UBS Securities said in a note e-mailed Friday. The brokerage forecasts better-than-expected bottom-line results for PennyMac Financial Services ( PFSI ) and loanDepot (LDI),...

Central Bancompany files for US IPO

Oct 10, 2025

Oct 10 (Reuters) - Bank holding company Central Bancompany on Friday filed for an initial public offering in the United States. ...

Strathcona Resources terminates takeover bid for MEG

Oct 10, 2025

Oct 10 (Reuters) - Strathcona Resources ( STHRF ) said on Friday it has terminated its takeover bid for MEG Energy ( MEGEF ) . ...

Zoetis Wins EU Backing for Dog Osteoarthritis Drug Lenivia

Oct 10, 2025

04:54 PM EDT, 10/10/2025 (MT Newswires) -- Zoetis ( ZTS ) said its Lenivia treatment for dogs with osteoarthritis pain received a positive opinion recommending marketing authorization from the European Medicines Agency's Committee for Veterinary Medicinal Products. A final decision from the European Commission is expected in Q4, with commercial availability anticipated in 2026, Zoetis ( ZTS ) said Friday...